Introduction
Viral infection may sometimes trigger the development of an inflammatory renal disease or worsening of pre-existing renal disease [1] . Mesangial cells produce a wide variety of pro-inflammatory molecules that play an important role in immune and inflammatory reactions in the kidney; however, the details of the anti-viral reactions of mesangial cells are not yet fully elucidated.
Retinoic acid-inducible gene-I (RIG-I) encodes a DExH box protein, which is an RNA helicase [2] . The DExH box family proteins regulate RNA metabolism and have various biological functions [3] . In particular, RIG-I may detect viral RNAs and mediate immune reactions against RNA viruses [4] . RIG-I is also suggested to be involved in immune and inflammatory responses in various physiological and disease conditions [5] .
A double-stranded RNA (dsRNA) is generated during replication cycle of certain viruses. Polyinosinic-polycytidylic acid (poly IC) is an authentic dsRNA, and both viral dsRNA and poly IC are potent inducers of type I interferons (IFNs) and the downstream molecules of the innate immune pathway. Therefore, poly IC has been widely used to mimic viral infection in various cell types, including dendritic cells [6] , T-cells [7] and mesangial cells [8] [9] [10] [11] .
Poly IC stimulates mesangial cells to express functional molecules such as interleukin (IL)-6 [8] , CC chemokine ligand (CCL) 2 (or monocyte-chemoattractant protein-1, MCP-1) [9] , CCL5 (or regulated on activation, normal Tcell expression and secretion, RANTES) [10] and matrix metalloproteinase 9 (MMP9) [11] .
We previously reported that poly IC induces the expression of RIG-I in human vascular endothelial cells [12] and human astrocytes [13] . We also found that IFN-γ induces the expression of RIG-I in human mesangial cells [14] . The present study was undertaken to evaluate the potential role of RIG-I in response to poly IC in human mesangial cells.
Materials and methods

Reagents
Poly IC and anti-actin rabbit IgG were from Sigma (St. Louis, MA, USA). The RNeasy total RNA isolation kit, small interfering RNAs (siRNA) against RIG-I (SI03019646) and Toll-like receptor (TLR) 3 (SI02655156), and non-silencing negative control siRNA (1027281) were from Qiagen (Hilden, Germany). Primer oligo(dT) [12] [13] [14] [15] [16] [17] [18] , dNTP mix, Moloney murine leukaemia virus (MMLV) reverse transcriptase, Lipofectamine 2000 and siRNA against IFN-β (5'-CCA UGA GCU ACA ACU UGU UGG AUU-'3 and 5'-AAU CCA AGC AAG UUG UAG CUC AUG G-'3) were purchased from Invitrogen (Frederick, MD, USA). Taq DNA polymerase was from Promega (Madison, WI, USA). Oligonucleotide primers for polymerase chain reaction (PCR) were custom synthesized by Greiner Japan (Atsugi, Japan). Recombinant human (r(h)) IFN-β was from ProSpec (Rehovot, Israel). Anti-RIG-I antibody was raised as according to previously described methods [3] . Monoclonal antibody against type I IFN receptor was from CALBIO-CHEM (La Jolla, CA, USA). FuGENE HD transfection reagent was from Roche Diagnostics (Basel, Switzerland). Dexamethasone was from Wako (Osaka, Japan). Enzyme-linked immunosorbent assay (ELISA) kits for CCL5 and IFN-β were from R&D Systems (Minneapolis, MN, USA) and Fujirebio (Tokyo, Japan), respectively.
Cells
Normal human mesangial cells and culture medium were purchased from Lonza (Walkersville, MD, USA), and the cells were cultured according to the manufacturer's protocol [12] . Poly IC was dissolved in phosphatebuffered saline (PBS), and the cells were treated with 0.08∼50 μg/mL of poly IC for up to 48 h. The cells were transfected with non-silencing control siRNA or siRNAs against RIG-I, IFN-β, or TLR3 by using Lipofectamine 2000 reagent. A pcDNA3.1-IFN-β expression construct was used for the transfection of normal human mesangial cells using FuGENE HD transfection reagent according to the manufacturer's protocol.
RNA extraction and reverse transcription-PCR analysis
The total RNA was extracted from cells using RNeasy RNA extraction kit. Single-strand cDNA was synthesized from 1 μg of the total RNA by using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and MMLV reverse transcriptase. The cDNAs for RIG-I, CCL5, CCL2, IFN-α, IFN-β, IFN-γ, TLR3 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were amplified by PCR using Taq DNA polymerase. The PCR primers used are shown in Table 1 .
Western blot analysis
Western blot analysis was performed as described in previous reports [3] . Briefly, the cells were lysed with Laemmli reducing sample buffer. The lysate was electrophoresed on a 7.5% or 10% polyacrylamide gel, and subsequently, the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with an antibody against RIG-I (1:10 000 dilution) or actin (1:250 dilution), and subsequently with horseradish peroxidase-labelled anti-rabbit IgG. Immunodetection was performed using a chemiluminescence substrate.
ELISA for CCL5 and IFN-β
The concentration of CCL5 or IFN-β in the cell-conditioned medium was measured using ELISA kits.
Results
Poly IC induces the expression of RIG-I in cultured human mesangial cells
The treatment of mesangial cells with poly IC induced the expression of RIG-I in a concentration-and time-dependent manner ( Figure 1 ). Stimulation with poly IC elevated the expression of both RIG-I mRNA and protein, reaching maximal expression levels ∼16 and 24 h post-stimulation, respectively ( Figure 1C and D). The expression of RIG-I protein remained high, but that of the mRNA decreased substantially 48 h after stimulation. Furthermore, the decay of RIG-I mRNA appeared to be faster than that of RIG-I protein. 
RIG-I siRNA suppresses poly IC-induced CCL5 expression in mesangial cells
The effect of RIG-I siRNA is shown in Figure 2 . Treatment with RIG-I siRNA, which effectively inhibited RIG-I expression (Figure 2A ), significantly lowered poly IC-induced CCL5 expression ( Figure 2B and C). The concentration of CCL5 protein in the culture medium of poly IC-treated cells was 100 ± 12 pg/10 5 cells, which was lowered to 35 ± 4 pg/10 5 cells (mean ± SD, n = 3; P < 0.01, Student's t-test) after RIG-I knockdown ( Figure 2C ). The poly IC-induced expression of CCL2 mRNA was not affected by RIG-I siRNA ( Figure 2B ).
TLR3 is involved in poly IC-induced RIG-I expression
The poly IC-induced RIG-I expression was suppressed in response to treatment with siRNA against TLR3 ( Figure 3A 
Dexamethasone inhibits the induction of RIG-I by poly IC
Pre-treatment of cells with dexamethasone reduced the poly IC-induced expression of both RIG-I and IFN-β ( Figure 6A and B), but this treatment had no effect on IFN-β-induced RIG-I expression ( Figure 6C ).
Discussion
It is believed that RIG-I controls immune and inflammatory responses by regulating the expressions of various downstream genes, including IFNs regulatory factor genes. It has also been suggested that RIG-I mediates the expression of CCL5 in poly IC-treated human astrocytes [13] and in rheumatoid synoviocytes treated with tumour-necrosis factor (TNF)-α [15] . However, in mesangial cells, RIG-I is not involved in poly IC-induced expression of IL-6 [8] or MMP9 [11] . In the present study, poly IC-induced CCL5 expression was partially inhibited in response to the knockdown of RIG-I. The expression of CCL2 was not affected by treatment with RIG-I siRNA, which may selectively regulate the expression of CCL5. CCL5 is a chemokine with chemotactic activity towards lymphocytes and monocytes; high levels of CCL5 mRNA are detected in urinary sediments of patients with lupus nephritis [16] . A recent report suggested that RIG-I, and not TLR3, mediates the secretion of type I IFN in poly IC-treated glomerular endothelial cells [17] . The cross-talk between glomerular endothelial cells and mesangial cells may be an important aspect of glomerular inflammation, and the RIG-I/CCL5 pathway in mesangial cells may contribute to glomerular inflammation, particularly after viral infection. IFNs are cytokines with anti-viral properties and potent agonistic activity towards RIG-I expression [18] . Generally, type I IFNs, which include IFN-α and IFN-β, are involved in innate immune responses, while the type II IFN-γ is essential for adaptive immune responses. In our previous study, we found that IFN-γ enhances RIG-I expression in mesangial cells [14] . IFN-β is reported to mediate the induction of RIG-I in lipopolysaccharide- stimulated RAW264.7 mouse macrophage-like cells [19] and in TNF-stimulated human synoviocytes [14] . Mesangial cells are known to produce IFN-β [8] . In the present study, treatment of mesangial cells with poly IC induced the expression of IFN-β but not affect the expression of IFN-α or IFN-γ. We found that siRNA-mediated knockdown of IFN-β was associated with the inhibition of poly IC-induced RIG-I expression. Blocking of type I IFN receptor with a specific antibody also inhibited the RIG-I expression. In addition, overexpression of IFN-β induced the expression of RIG-I and CCL5. These results suggest that newly synthesized IFN-β is involved in poly IC-induced RIG-I expression.
Both TLR3 and RIG-I are reported to serve as receptors for dsRNA [4, 20] ; furthermore, TLR3 is suggested to be involved in virus-associated renal inflammation [8, 11] . In the present study, siRNA-mediated knockdown of TLR3 inhibited the poly IC-induced expression of both IFN-β and RIG-I. However, RIG-I knockdown had no effect on poly IC-induced IFN-β expression. Thus, RIG-I may function downstream to TLR3 in the signalling cascade activated by poly IC-induced expression of CCL5 in mesangial cells. In our previous study, we had observed high levels of RIG-I expression in the glomeruli and urinary sediments of patients with lupus nephritis [21, 22] . RIG-I overexpression may be a pathological feature of renal inflammatory diseases, and CCL5 may serve as an effector molecule in such diseases.
Anti-inflammatory steroids are frequently used for the treatment of renal diseases, and dexamethasone was found to inhibit the poly IC-induced expression of IFN-β and RIG-I. Since dexamethasone had no effect on IFN-β-induced RIG-I expression, the inhibitory effect of dexamethasone may depend on the suppression of IFN-β production.
We conclude that poly IC induces the expression of RIG-I in cultured human mesangial cells, thereby upregulating CCL5 expression. TLR3 and newly synthesized IFN-β are involved in poly IC-induced RIG-I expression. On the basis of these results, we propose the TLR3/IFN-β/ RIG-I/CCL5 pathway ( Figure 7 ). The involvement of the TLR3/IFN-β/RIG-I/CCL5 pathway in poly IC signalling in mesangial cells is a novel finding, and this pathway may play an important role in immune and inflammatory reactions against viral infection in mesangial cells. 
